Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Sakti Chakrabarti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1582-098X; OpenAlex author ID A5078997248. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper

Papers 8

  1. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  2. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Co-author DOI 10.1016/j.hpb.2023.07.903↗
  3. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  4. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. Co-author DOI 10.1200/po.23.00092↗
  5. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. Co-author DOI 10.1136/jitc-2021-004485↗
  6. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Co-author DOI 10.3390/cancers14112588↗
  7. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.soc.2021.06.004↗
  8. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Last author DOI 10.7759/cureus.14640↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amit Mahipal · 5 shared papers, 2021–2023 · strength 0.99
  2. Mandana Kamgar · 3 shared papers, 2021–2024 · strength 0.63
  3. Ben George · 2 shared papers, 2021–2024 · strength 0.36
  4. Jason Scott Starr · 2 shared papers, 2022–2023 · strength 0.32
  5. Ronald E Cox · 1 shared paper, 2021 · strength 0.22
  6. Bradley A. Erickson · 1 shared paper, 2024 · strength 0.17
  7. William Adrian Hall · 1 shared paper, 2024 · strength 0.17
  8. Callisia Nathelee Clarke · 1 shared paper, 2024 · strength 0.17
  9. Saryleine Ortiz de Choudens · 1 shared paper, 2024 · strength 0.17
  10. Mohammed Aldakkak · 1 shared paper, 2024 · strength 0.17
  11. Douglas B. Evans · 1 shared paper, 2024 · strength 0.17
  12. Kulwinder S. Dua · 1 shared paper, 2024 · strength 0.17
  13. Susan Tsai · 1 shared paper, 2024 · strength 0.17
  14. Kathleen K. Christians · 1 shared paper, 2024 · strength 0.17
  15. John Andrew Stauffer · 1 shared paper, 2023 · strength 0.17
  16. Aakash P. Desai · 1 shared paper, 2023 · strength 0.17
  17. Tucker W. Coston · 1 shared paper, 2023 · strength 0.17
  18. Mohamad Bassam Sonbol · 1 shared paper, 2023 · strength 0.17
  19. Mohamedraed Elshami · 1 shared paper, 2023 · strength 0.17
  20. Richard S. Hoehn · 1 shared paper, 2023 · strength 0.17
  21. John Brian Ammori · 1 shared paper, 2023 · strength 0.17
  22. David Lawrence Bajor · 1 shared paper, 2023 · strength 0.17
  23. Lee Mayer Ocuin · 1 shared paper, 2023 · strength 0.17
  24. Hani M. Babiker · 1 shared paper, 2023 · strength 0.17
  25. Jeffrey M. Hardacre · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.